Developer docs
API playgroundTry for free, no card

Search company profiles

imusyn

Full company profile

uuid002riyi

Namestring
imusyn
Legal namestring
imusyn GmbH & Co. KG
Websiteurl
imusyn.de
Company typeenum
Private
Founded yearint
2001
Descriptiontext

imusyn GmbH & Co. KG is a privately held German biotechnology company founded in 2001 in Hannover that develops and produces recombinant proteins, diagnostic reagents, and T cell staining tools for transfusion medicine, organ transplantation, and immunology research. Its proprietary alloproteomics platform enables high-yield, massively parallel production of recombinant proteins from polymorphic genetic systems — including nearly 100 HLA class I variants, over 70 HLA class II variants, and recombinant blood group antigens (rBGA) — using eukaryotic and prokaryotic expression hosts under a DIN EN ISO 13485 quality management system. Flagship products include the CE-marked IVD reagent DaraEx plus (a patented antigen-masking reagent that overcomes anti-CD38 antibody interference from Daratumumab, Felzartamab, and Isatuximab in pre-transfusion indirect antiglobulin tests), Dyemer and myDyemer T cell staining reagents built on patent-pending disulfide-bridge stabilised HLA class I molecules, and a portfolio of monoclonal antibodies (BBM.1, W6/32 HL, TÜ113, TÜ36, TÜ39).

The company serves three primary customer segments: (1) academic and industrial life sciences researchers and diagnostic assay developers using recombinant HLA proteins and T cell staining reagents for antibody detection, vaccine development, and cancer immunotherapy research; (2) IVD manufacturers and immunohematology laboratories, supplied with CE-marked reagents and recombinant blood group antigens; and (3) vaccine and cellular therapy developers, served by the imuPep peptide/HLA class I binding stability service. Customer relationships include BAG Healthcare (HLA proteins used in HISTO SPOT chip products), with named research use cases also spanning immunology, HLA typing, and T cell immunomonitoring. Product ranges are listed on a downloadable order-form e-commerce shop at imusyn.de, supported by downloadable IFUs in 15 languages for the CE-marked DaraEx plus line.

Revenue is generated through one-time catalog sales of recombinant proteins, RUO reagents, and CE-marked IVD reagents; service fees for imuPep peptide binding analysis, IVD consulting, design & development, and custom recombinant protein production (DIN EN ISO 13485); and quote-based bespoke projects. Distribution is hybrid: a direct online storefront handles RUO catalog sales, while an exclusive distribution partnership with inno-train Diagnostik GmbH (Kronberg, Germany) carries DaraEx plus, DaraEx, and rBGA into European clinical and diagnostic laboratories. Standard catalog pricing (e.g., €944 per 50 µg HLA class II protein, €65 per imuPep peptide/allotype combination) and a €40 handling fee for EU orders under €500 indicate a distributed, transactional revenue model. The company has received an IVDR Confirmation Letter under Regulation (EU) 2024/1860 (May 22, 2025), transitioning CE-marked IVDs under the new regulatory framework with a deadline of December 31, 2027, and holds an EFRE grant supporting the next-generation imuStain multimer staining platform.

Short descriptiontext

imusyn GmbH & Co. KG is a Hannover-based German biotechnology company that develops and manufactures recombinant HLA proteins, CE-marked IVD reagents (DaraEx plus) for transfusion medicine, and Dyemer/myDyemer T cell staining reagents for immunology research, IVD manufacturers, and cellular therapy developers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersHanover, Germany
HQ citystring
Hanover
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
Recombinant HLA proteins, Transfusion medicine diagnostics, Immunohematology reagents, T cell staining reagents, Custom protein manufacturing
Industry3 codes
PRIMARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAHAAAM
IVD Reagents, Assay Kits & Consumables (Non-instrument)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical and Diagnostic Laboratories62151
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Transfusion Medicine & Transplantation Diagnostics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model6 records
1Recombinant Protein Sales (HLA, rBGA)
TypeOne Time License
Description

Sale of recombinant HLA class I proteins (nearly 100 variants), HLA class II proteins (over 70 variants), recombinant blood group antigens (rBGA), and T cell staining reagents (Dyemer/myDyemer) as research use only (RUO) products. Products are sold via the company's online shop and through distribution partners. Customers include life sciences researchers, diagnostic assay developers, and IVD manufacturers.

imusyn.de
2DaraEx / DaraEx plus IVD Diagnostic Reagent Sales
TypeOne Time License
Description

DaraEx plus is sold as a CE-marked IVD medical device through distribution partner inno-train Diagnostik GmbH. DaraEx (RUO) is also available through the same distributor. Revenue is generated through product sales to immunohematology laboratories and blood transfusion services.

imusyn.de
3imuPep Class I Peptide Binding Analysis Service
TypeProfessional Services
Description

Fee-for-service high-throughput peptide/HLA class I binding stability analysis. Customers can order per peptide/HLA allotype combination. Peptide synthesis can be added as an optional service. The service is quoted and ordered via downloadable order form.

imusyn.de
4IVD Consulting Services
TypeProfessional Services
Description

Regulatory consulting for in-vitro diagnostic development, including technical documentation preparation and compliance support under European IVDR. Supports clients from concept through CE marking.

imusyn.de
5Custom Recombinant Protein Production
TypeProfessional Services
Description

Full-service custom recombinant protein production under DIN EN ISO 13485. Clients can enter the process at any stage: gene cloning, cell line cultivation, or purification of crude material. Offered as a bespoke service with project-based pricing.

imusyn.de
6Design & Development Consulting
TypeProfessional Services
Description

Protein design and antigen development consulting, including optimisation of protein stability, epitope expression, and production yields. Provided either as an in-house service or as on-site consulting at the client's company.

imusyn.de
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Pricing details5 tiers
1Recombinant HLA Class II Proteins (e.g., HLA-DQA1*01:01-DQB1*06:02) — 50 µg unit at 0.5 mg/ml
ModelUnit PricingBilling cadencePay-as-you-go
Notes

944 € per unit (excluding VAT). Quantity: 50 µg at 0.5 mg/ml concentration. Liquid formulation in phosphate-based buffer with preservative. Grade: RUO.

imusyn.de
2EU Shipping and Handling Fee
ModelUnit PricingBilling cadencePay-as-you-go
Notes

40€ handling and shipping fee for orders under 500€ within the EU. Free handling and shipping for orders over 500€ within the EU.

imusyn.de
3imuPep Class I Peptide Binding Analysis — per peptide/allotype combination
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Peptide binding analysis: 65€ per peptide/allotype combination. If binding cannot be confirmed, no charge is incurred. Additional peptide synthesis available at separate pricing depending on peptide length.

imusyn.de
4Peptide Synthesis Service (for imuPep)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Peptide synthesis pricing depends on total peptide length. Includes reconstitution of lyophilized product. Lead time approximately four weeks. Peptides are used for Differential Scanning Fluorometry.

imusyn.de
5Custom/HLA alleles and T cell staining reagents not in catalog
ModelOtherBilling cadencePay-as-you-go
Notes

Custom alleles, extended panel Dyemer/myDyemer products, and catalog items not listed are quote-based. Customers contact via contact form or request form for personal quotation.

imusyn.de
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1DaraEx
Description

Patented reagent to overcome anti-CD38 antibody interference in immunohematological pre-transfusion testing, including DaraEx plus (CE marked IVD) and DaraEx (RUO).

imusyn.de
+4 more records
Core offering1 text field

imusyn develops and manufactures recombinant proteins and IVD reagents for transfusion medicine and organ transplantation. Its core offerings include nearly 100 recombinant HLA class I proteins, over 70 HLA class II proteins, the DaraEx/DaraEx plus line of IVD reagents that overcome anti-CD38 antibody interference in pre-transfusion testing, and Dyemer/myDyemer T cell staining reagents for antigen-specific CD8+ T cell detection. The company also delivers fee-for-service peptide binding analysis, IVD consulting, custom recombinant protein production, and protein design and development services under DIN EN ISO 13485 quality management.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • DaraEx and DaraEx plus successfully mitigate interference from anti-CD38 antibodies (Daratumumab, Felzartamab, Isatuximab) in indirect antiglobulin tests without affecting detection of other clinically relevant antibodies (e.g., anti-Kell)
+1 more record
Product overview1 text field

imusyn is a biotechnology company specializing in recombinant proteins for transfusion medicine and organ transplantation diagnostics. The product portfolio centers on three main areas: (1) Recombinant HLA Class I and Class II proteins (nearly 100 and over 70 molecules respectively) for antibody detection in transplantation; (2) DaraEx and DaraEx plus — patented IVD reagents that overcome anti-CD38 antibody interference in pre-transfusion testing; and (3) Dyemer and myDyemer — novel T cell staining reagents for antigen-specific CD8+ T cell detection. The company also offers monoclonal antibodies (W6/32 HL, BBM.1, TÜ113, TÜ36, TÜ39) for research use. Services include imuPep Class I Peptide Binding Analysis (high-throughput peptide/HLA stability testing), IVD Consulting, Design & Development, and Custom Production — all delivered under DIN EN ISO 13485 quality management.

Product and service12 records
1Recombinant HLA Class I Proteins
CategoryRecombinant Proteins / Research Reagents
Description

Recombinant, truncated, soluble HLA class I proteins produced in mammalian cell culture for antibody detection in transplantation and transfusion medicine. imusyn offers nearly 100 recombinant HLA class I molecules including HLA-A, HLA-B, and HLA-C alleles, sold for research use only (RUO).

2Recombinant HLA Class II Proteins
CategoryRecombinant Proteins / Research Reagents
Description

Recombinant HLA class II proteins (DR, DP, DQ antigens) produced as zipper-stabilized heterodimers in mammalian cell culture for use in antibody detection and immunoassays. Over 70 recombinant HLA class II molecules are available for research use only (RUO).

3DaraEx plus
CategoryIn-Vitro Diagnostic Reagents
Description

CE-marked IVD reagent that overcomes anti-CD38 antibody interference (Daratumumab, Felzartamab, Isatuximab) in indirect antiglobulin tests (IAT) using patented antigen-masking (AMIAT) technology. Sold as a one-step treatment for red blood cells in pre-transfusion compatibility testing.

4DaraEx
CategoryResearch Reagents
Description

Research use only (RUO) reagent for overcoming anti-CD38 antibody interference in pre-transfusion testing using the same patented antigen-masking technology as DaraEx plus.

5Dyemer
CategoryT Cell Staining Reagents
Description

Novel T cell staining reagent for detection and enumeration of antigen-specific CD8+ T cells. Comprises recombinant MHC class I molecules expressed in mammalian cell culture with authentic glycosylation, coupled to fluorophore-labeled streptavidin (PE or APC conjugate). Features reversible staining capability via biotin incubation.

6myDyemer
CategoryT Cell Staining Reagents
Description

Peptide-receptive, pre-multimerized T cell staining reagent that remains stable in a peptide-deficient state, allowing users to load their peptide of interest by single-step peptide addition without refolding assays. Based on imuStain disulfide-bridge-stabilised HLA class I technology.

7Monoclonal Antibodies
CategoryResearch Antibodies
Description

Research use monoclonal antibodies including BBM.1 (Beta-2-microglobulin), PR1F11F11 (V5-tag), W6/32 HL (MHC class I), TÜ113 (HLA class I), TÜ36 (HLA class II), and TÜ39 (HLA class II), available unconjugated or HRP-conjugated.

8Recombinant Blood Group Antigens (rBGA)
CategoryRecombinant Proteins / Research Reagents
Description

Recombinant blood group antigens available for research use only (RUO), distributed through inno-train Diagnostik GmbH for antibody detection applications in immunohematology.

9imuPep Class I Peptide Binding Analysis
CategoryAnalytical Services
Description

High-throughput fee-for-service using differential scanning fluorimetry (DSF) and native PAGE to determine the stability of peptide/HLA class I complexes. Supports over 60 HLA class I allotypes for rapid assessment of immunogenic peptide stability in vaccine development, cancer research, and T cell epitope identification.

10IVD Consulting
CategoryConsulting Services
Description

Regulatory and technical consulting for the development and production of in-vitro diagnostic tests, including technical documentation preparation and CE marking support under the European IVDR.

11Design & Development
CategoryConsulting Services
Description

Expertise in protein design and antigen development to optimize protein stability, epitope expression, and production yields. Delivered either as an in-house service or as on-site consulting at the client's site.

12Custom Production
CategoryCustom Manufacturing Services
Description

Full-service custom recombinant protein production in accordance with DIN EN ISO 13485, covering all stages from gene cloning and cell line cultivation through purification of crude material. Clients can enter the process at any stage.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

inno-train Diagnostik GmbH is the exclusive distribution partner for imusyn's DaraEx plus (CE-marked IVD), DaraEx (RUO), and rBGA products. The partnership extends imusyn's commercial reach into clinical laboratory and diagnostic markets across Europe. Located at Niederhöchstädter Str. 62, 61476 Kronberg, Germany. DaraEx plus is available from inno-train's retail portal at www.inno-train.de.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

GenDx develops and commercializes HLA typing and antibody detection reagents for transplantation diagnostics. Its SBT and NGS-based HLA products overlap with imusyn's recombinant HLA protein portfolio serving transplant and immunohematology laboratories.

2One Lambda (Thermo Fisher Scientific)
TypeBroad incumbent
Description

One Lambda, part of Thermo Fisher Scientific, is a leading provider of HLA typing, antibody detection, and transplant diagnostics products. It is a broader incumbent with overlapping HLA antibody detection reagents that compete with imusyn's recombinant HLA portfolio.

TypeBroad incumbent
Description

Miltenyi Biotec supplies reagents and instruments for cell analysis, including MHC multimers and T cell research tools. It overlaps with imusyn's Dyemer/myDyemer reagents and serves similar immunology and cell therapy research customers.

TypeEmerging player
Description

Creative Biolabs offers custom recombinant protein production and MHC/peptide reagent services for research use. It is an emerging player overlapping with imusyn's custom production and recombinant HLA protein catalog offerings.

TypeBroad incumbent
Description

Bio-Rad offers a broad portfolio of blood bank and HLA typing products through its diagnostics division. Its size and commercial reach make it a broad incumbent competitor to imusyn's immunohematology and transplantation diagnostics products.

TypeDirect peer
Description

ProImmune supplies MHC tetramers, peptide binding assays (REVEAL®), and recombinant HLA proteins for immunology research and immunotherapy development. It is the closest direct competitor to imusyn's Dyemer/myDyemer multimer staining reagents and imuPep peptide binding analysis service.

TypeEmerging player
Description

CellGenix manufactures recombinant proteins and cell therapy manufacturing reagents under GMP. It shares imusyn's focus on high-quality recombinant protein production and serves adjacent cell and gene therapy developers.

TypeOthers
Description

inno-train Diagnostik is imusyn's exclusive distribution partner for DaraEx plus, DaraEx, and rBGA products. It is an ecosystem participant and adjacent supplier of flow cytometry and HLA diagnostic reagents in Europe.

TypeDirect peer
Description

Immucor is a specialist in transfusion and transplantation diagnostics, offering blood bank reagents and HLA antibody detection assays. It competes with imusyn's DaraEx plus and recombinant blood group antigens in the immunohematology laboratory market.

TypeOthers
Description

BAG Healthcare is an imusyn customer that integrates imusyn's recombinant HLA proteins into its HISTO SPOT diagnostic chip products. It is thematically adjacent as a downstream IVD manufacturer in transplantation diagnostics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature10 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

imusyn

Transfusion Medicine & Transplantation Diagnosticsimusyn.de

imusyn GmbH & Co. KG is a Hannover-based German biotechnology company that develops and manufactures recombinant HLA proteins, CE-marked IVD reagents (DaraEx plus) for transfusion medicine, and Dyemer/myDyemer T cell staining reagents for immunology research, IVD manufacturers, and cellular therapy developers.

What imusyn does

imusyn GmbH & Co. KG is a privately held German biotechnology company founded in 2001 in Hannover that develops and produces recombinant proteins, diagnostic reagents, and T cell staining tools for transfusion medicine, organ transplantation, and immunology research. Its proprietary alloproteomics platform enables high-yield, massively parallel production of recombinant proteins from polymorphic genetic systems — including nearly 100 HLA class I variants, over 70 HLA class II variants, and recombinant blood group antigens (rBGA) — using eukaryotic and prokaryotic expression hosts under a DIN EN ISO 13485 quality management system. Flagship products include the CE-marked IVD reagent DaraEx plus (a patented antigen-masking reagent that overcomes anti-CD38 antibody interference from Daratumumab, Felzartamab, and Isatuximab in pre-transfusion indirect antiglobulin tests), Dyemer and myDyemer T cell staining reagents built on patent-pending disulfide-bridge stabilised HLA class I molecules, and a portfolio of monoclonal antibodies (BBM.1, W6/32 HL, TÜ113, TÜ36, TÜ39).

The company serves three primary customer segments: (1) academic and industrial life sciences researchers and diagnostic assay developers using recombinant HLA proteins and T cell staining reagents for antibody detection, vaccine development, and cancer immunotherapy research; (2) IVD manufacturers and immunohematology laboratories, supplied with CE-marked reagents and recombinant blood group antigens; and (3) vaccine and cellular therapy developers, served by the imuPep peptide/HLA class I binding stability service. Customer relationships include BAG Healthcare (HLA proteins used in HISTO SPOT chip products), with named research use cases also spanning immunology, HLA typing, and T cell immunomonitoring. Product ranges are listed on a downloadable order-form e-commerce shop at imusyn.de, supported by downloadable IFUs in 15 languages for the CE-marked DaraEx plus line.

Revenue is generated through one-time catalog sales of recombinant proteins, RUO reagents, and CE-marked IVD reagents; service fees for imuPep peptide binding analysis, IVD consulting, design & development, and custom recombinant protein production (DIN EN ISO 13485); and quote-based bespoke projects. Distribution is hybrid: a direct online storefront handles RUO catalog sales, while an exclusive distribution partnership with inno-train Diagnostik GmbH (Kronberg, Germany) carries DaraEx plus, DaraEx, and rBGA into European clinical and diagnostic laboratories. Standard catalog pricing (e.g., €944 per 50 µg HLA class II protein, €65 per imuPep peptide/allotype combination) and a €40 handling fee for EU orders under €500 indicate a distributed, transactional revenue model. The company has received an IVDR Confirmation Letter under Regulation (EU) 2024/1860 (May 22, 2025), transitioning CE-marked IVDs under the new regulatory framework with a deadline of December 31, 2027, and holds an EFRE grant supporting the next-generation imuStain multimer staining platform.

imusyn firmographics

Firmographics
Name
imusyn
Legal name
imusyn GmbH & Co. KG
Website
https://imusyn.de
Company type
Private
Founded year
2001
Operating status
Operating
Headcount range
1–10 employees
Short description
imusyn GmbH & Co. KG is a Hannover-based German biotechnology company that develops and manufactures recombinant HLA proteins, CE-marked IVD reagents (DaraEx plus) for transfusion medicine, and Dyemer/myDyemer T cell staining reagents for immunology research, IVD manufacturers, and cellular therapy developers.
Ownership category
akta.pro rank

imusyn industry classification

Industry
Product category
Transfusion Medicine & Transplantation Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (62151)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAHAAAM
IVD Reagents, Assay Kits & Consumables (Non-instrument)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)

Keywords

  • Recombinant HLA proteins
  • Transfusion medicine diagnostics
  • Immunohematology reagents
  • T cell staining reagents
  • Custom protein manufacturing

Where imusyn is headquartered

Location

Headquarters

HQ city
Hanover
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

imusyn business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Recombinant Protein Sales (HLA, rBGA): Sale of recombinant HLA class I proteins (nearly 100 variants), HLA class II proteins (over 70 variants), recombinant blood group antigens (rBGA), and T cell staining reagents (Dyemer/myDyemer) as research use only (RUO) products. Products are sold via the company's online shop and through distribution partners. Customers include life sciences researchers, diagnostic assay developers, and IVD manufacturers.
  2. DaraEx / DaraEx plus IVD Diagnostic Reagent Sales: DaraEx plus is sold as a CE-marked IVD medical device through distribution partner inno-train Diagnostik GmbH. DaraEx (RUO) is also available through the same distributor. Revenue is generated through product sales to immunohematology laboratories and blood transfusion services.
  3. imuPep Class I Peptide Binding Analysis Service: Fee-for-service high-throughput peptide/HLA class I binding stability analysis. Customers can order per peptide/HLA allotype combination. Peptide synthesis can be added as an optional service. The service is quoted and ordered via downloadable order form.
  4. IVD Consulting Services: Regulatory consulting for in-vitro diagnostic development, including technical documentation preparation and compliance support under European IVDR. Supports clients from concept through CE marking.
  5. Custom Recombinant Protein Production: Full-service custom recombinant protein production under DIN EN ISO 13485. Clients can enter the process at any stage: gene cloning, cell line cultivation, or purification of crude material. Offered as a bespoke service with project-based pricing.
  6. Design & Development Consulting: Protein design and antigen development consulting, including optimisation of protein stability, epitope expression, and production yields. Provided either as an in-house service or as on-site consulting at the client's company.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goRecombinant HLA Class II Proteins (e.g., HLA-DQA1*01:01-DQB1*06:02) — 50 µg unit at 0.5 mg/ml
Unit PricingPay-as-you-goEU Shipping and Handling Fee
Unit PricingPay-as-you-goimuPep Class I Peptide Binding Analysis — per peptide/allotype combination
Unit PricingPay-as-you-goPeptide Synthesis Service (for imuPep)
OtherPay-as-you-goCustom/HLA alleles and T cell staining reagents not in catalog

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

imusyn product offering

Product offering

Core offering

imusyn develops and manufactures recombinant proteins and IVD reagents for transfusion medicine and organ transplantation. Its core offerings include nearly 100 recombinant HLA class I proteins, over 70 HLA class II proteins, the DaraEx/DaraEx plus line of IVD reagents that overcome anti-CD38 antibody interference in pre-transfusion testing, and Dyemer/myDyemer T cell staining reagents for antigen-specific CD8+ T cell detection. The company also delivers fee-for-service peptide binding analysis, IVD consulting, custom recombinant protein production, and protein design and development services under DIN EN ISO 13485 quality management.

Product overview

imusyn is a biotechnology company specializing in recombinant proteins for transfusion medicine and organ transplantation diagnostics. The product portfolio centers on three main areas: (1) Recombinant HLA Class I and Class II proteins (nearly 100 and over 70 molecules respectively) for antibody detection in transplantation; (2) DaraEx and DaraEx plus — patented IVD reagents that overcome anti-CD38 antibody interference in pre-transfusion testing; and (3) Dyemer and myDyemer — novel T cell staining reagents for antigen-specific CD8+ T cell detection. The company also offers monoclonal antibodies (W6/32 HL, BBM.1, TÜ113, TÜ36, TÜ39) for research use. Services include imuPep Class I Peptide Binding Analysis (high-throughput peptide/HLA stability testing), IVD Consulting, Design & Development, and Custom Production — all delivered under DIN EN ISO 13485 quality management.

Differentiator

Problem solved

Functional benefit

Brands

  • DaraEx: Patented reagent to overcome anti-CD38 antibody interference in immunohematological pre-transfusion testing, including DaraEx plus (CE marked IVD) and DaraEx (RUO).
  • Dyemer & myDyemer
  • imuStain
  • imuPep
  • rBGA

Products and services

  • Recombinant HLA Class I Proteins Recombinant, truncated, soluble HLA class I proteins produced in mammalian cell culture for antibody detection in transplantation and transfusion medicine. imusyn offers nearly 100 recombinant HLA class I molecules including HLA-A, HLA-B, and HLA-C alleles, sold for research use only (RUO).
  • Recombinant HLA Class II Proteins Recombinant HLA class II proteins (DR, DP, DQ antigens) produced as zipper-stabilized heterodimers in mammalian cell culture for use in antibody detection and immunoassays. Over 70 recombinant HLA class II molecules are available for research use only (RUO).
  • DaraEx plus CE-marked IVD reagent that overcomes anti-CD38 antibody interference (Daratumumab, Felzartamab, Isatuximab) in indirect antiglobulin tests (IAT) using patented antigen-masking (AMIAT) technology. Sold as a one-step treatment for red blood cells in pre-transfusion compatibility testing.
  • DaraEx Research use only (RUO) reagent for overcoming anti-CD38 antibody interference in pre-transfusion testing using the same patented antigen-masking technology as DaraEx plus.
  • Dyemer Novel T cell staining reagent for detection and enumeration of antigen-specific CD8+ T cells. Comprises recombinant MHC class I molecules expressed in mammalian cell culture with authentic glycosylation, coupled to fluorophore-labeled streptavidin (PE or APC conjugate). Features reversible staining capability via biotin incubation.
  • myDyemer Peptide-receptive, pre-multimerized T cell staining reagent that remains stable in a peptide-deficient state, allowing users to load their peptide of interest by single-step peptide addition without refolding assays. Based on imuStain disulfide-bridge-stabilised HLA class I technology.
  • Monoclonal Antibodies Research use monoclonal antibodies including BBM.1 (Beta-2-microglobulin), PR1F11F11 (V5-tag), W6/32 HL (MHC class I), TÜ113 (HLA class I), TÜ36 (HLA class II), and TÜ39 (HLA class II), available unconjugated or HRP-conjugated.
  • Recombinant Blood Group Antigens (rBGA) Recombinant blood group antigens available for research use only (RUO), distributed through inno-train Diagnostik GmbH for antibody detection applications in immunohematology.
  • imuPep Class I Peptide Binding Analysis High-throughput fee-for-service using differential scanning fluorimetry (DSF) and native PAGE to determine the stability of peptide/HLA class I complexes. Supports over 60 HLA class I allotypes for rapid assessment of immunogenic peptide stability in vaccine development, cancer research, and T cell epitope identification.
  • IVD Consulting Regulatory and technical consulting for the development and production of in-vitro diagnostic tests, including technical documentation preparation and CE marking support under the European IVDR.
  • Design & Development Expertise in protein design and antigen development to optimize protein stability, epitope expression, and production yields. Delivered either as an in-house service or as on-site consulting at the client's site.
  • Custom Production Full-service custom recombinant protein production in accordance with DIN EN ISO 13485, covering all stages from gene cloning and cell line cultivation through purification of crude material. Clients can enter the process at any stage.

Quantifiable outcome

  • DaraEx and DaraEx plus successfully mitigate interference from anti-CD38 antibodies (Daratumumab, Felzartamab, Isatuximab) in indirect antiglobulin tests without affecting detection of other clinically relevant antibodies (e.g., anti-Kell)
  • +1 more outcomes

Companies that use imusyn

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

imusyn technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature10 records

imusyn partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • inno-train Diagnostik GmbHcoreChannel Partner/ Reseller/ Distributorinno-train Diagnostik GmbH is the exclusive distribution partner for imusyn's DaraEx plus (CE-marked IVD), DaraEx (RUO), and rBGA products. The partnership extends imusyn's commercial reach into clinical laboratory and diagnostic markets across Europe. Located at Niederhöchstädter Str. 62, 61476 Kronberg, Germany. DaraEx plus is available from inno-train's retail portal at www.inno-train.de.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

imusyn competitors and assessment

Company assessment

Direct peers

  • GenDx: GenDx develops and commercializes HLA typing and antibody detection reagents for transplantation diagnostics. Its SBT and NGS-based HLA products overlap with imusyn's recombinant HLA protein portfolio serving transplant and immunohematology laboratories.
  • ProImmune: ProImmune supplies MHC tetramers, peptide binding assays (REVEAL®), and recombinant HLA proteins for immunology research and immunotherapy development. It is the closest direct competitor to imusyn's Dyemer/myDyemer multimer staining reagents and imuPep peptide binding analysis service.
  • Immucor: Immucor is a specialist in transfusion and transplantation diagnostics, offering blood bank reagents and HLA antibody detection assays. It competes with imusyn's DaraEx plus and recombinant blood group antigens in the immunohematology laboratory market.

Broad incumbents

  • One Lambda (Thermo Fisher Scientific): One Lambda, part of Thermo Fisher Scientific, is a leading provider of HLA typing, antibody detection, and transplant diagnostics products. It is a broader incumbent with overlapping HLA antibody detection reagents that compete with imusyn's recombinant HLA portfolio.
  • Miltenyi Biotec: Miltenyi Biotec supplies reagents and instruments for cell analysis, including MHC multimers and T cell research tools. It overlaps with imusyn's Dyemer/myDyemer reagents and serves similar immunology and cell therapy research customers.
  • Bio-Rad Laboratories: Bio-Rad offers a broad portfolio of blood bank and HLA typing products through its diagnostics division. Its size and commercial reach make it a broad incumbent competitor to imusyn's immunohematology and transplantation diagnostics products.

Emerging players

  • Creative Biolabs: Creative Biolabs offers custom recombinant protein production and MHC/peptide reagent services for research use. It is an emerging player overlapping with imusyn's custom production and recombinant HLA protein catalog offerings.
  • CellGenix: CellGenix manufactures recombinant proteins and cell therapy manufacturing reagents under GMP. It shares imusyn's focus on high-quality recombinant protein production and serves adjacent cell and gene therapy developers.

Others

  • inno-train Diagnostik GmbH: inno-train Diagnostik is imusyn's exclusive distribution partner for DaraEx plus, DaraEx, and rBGA products. It is an ecosystem participant and adjacent supplier of flow cytometry and HLA diagnostic reagents in Europe.
  • BAG Healthcare: BAG Healthcare is an imusyn customer that integrates imusyn's recombinant HLA proteins into its HISTO SPOT diagnostic chip products. It is thematically adjacent as a downstream IVD manufacturer in transplantation diagnostics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

imusyn social profiles

Digital presence

imusyn compliance and trust

Trust signal

Compliance3 records

imusyn financial estimates

Financial estimate

Revenue estimate

Valuation estimate

imusyn leadership team

Management profile

Number of profiles

Profiles2 records

imusyn funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

imusyn M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about imusyn

What does imusyn do?

imusyn develops and manufactures recombinant proteins and IVD reagents for transfusion medicine and organ transplantation. Its core offerings include nearly 100 recombinant HLA class I proteins, over 70 HLA class II proteins, the DaraEx/DaraEx plus line of IVD reagents that overcome anti-CD38 antibody interference in pre-transfusion testing, and Dyemer/myDyemer T cell staining reagents for antigen-specific CD8+ T cell detection. The company also delivers fee-for-service peptide binding analysis, IVD consulting, custom recombinant protein production, and protein design and development services under DIN EN ISO 13485 quality management.

Is imusyn a public or private company?

imusyn is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was imusyn founded?

imusyn was founded in 2001. It employs 1 to 10 people.

Where is imusyn based?

imusyn is headquartered in Hanover, Germany, in the Europe region.

How does imusyn make money?

Six revenue lines are on record. Recombinant Protein Sales (HLA, rBGA) is the primary driver. The others are daraEx / DaraEx plus IVD Diagnostic Reagent Sales, imuPep Class I Peptide Binding Analysis Service, IVD Consulting Services, custom Recombinant Protein Production and design & Development Consulting.

Who are imusyn's main competitors?

Direct peers on record are GenDx, ProImmune and Immucor. Broad incumbents are One Lambda (Thermo Fisher Scientific), Miltenyi Biotec and Bio-Rad Laboratories. Emerging players are Creative Biolabs and CellGenix. Others are inno-train Diagnostik GmbH and BAG Healthcare.

Does imusyn have an API?

No public API is recorded for imusyn.

What industry is imusyn in?

imusyn's product category is Transfusion Medicine & Transplantation Diagnostics. Its primary akta.pro industry code is HLAAAMAL, Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls), with a secondary code of HLAHAAAM, IVD Reagents, Assay Kits & Consumables (Non-instrument). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales